PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy.
Wang S, Su D, Chen H, Lai JC, Tang C, Li Y, Wang Y, Yang Y, Qin M, Jia L, Cui W, Yang J, Wang L, Wu C.,

Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.
Tsuneyoshi N, Hosoya T, Takeno Y, Saitoh K, Murai H, Amimoto N, Tatsumi R, Watanabe S, Hasegawa Y, Kikkawa E, Goto K, Nishigaki F, Tamura K, Kimura H., Free PMC Article

An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.
Dioken DN, Ozgul I, Yilmazbilek I, Yakicier MC, Karaca E, Erson-Bensan AE., Free PMC Article

PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma.
Matsubara E, Shinchi Y, Komohara Y, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzuki M.

Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
Kuol N, Godlewski J, Kmiec Z, Vogrin S, Fraser S, Apostolopoulos V, Nurgali K., Free PMC Article

Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
Lv J, Jiang Z, Yuan J, Zhuang M, Guan X, Liu H, Yin Y, Ma Y, Liu Z, Wang H, Wang X., Free PMC Article

PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells.
Larsen TV, Daugaard TF, Gad HH, Hartmann R, Nielsen AL.

The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO, Tepeoğlu M, Özen Ö, Reyhan ANH, Ayhan A.

The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A, Yılmaz Akçay E, Özen Ö, Haberal Reyhan AN, Ayhan A.

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, Ren Y, Zhou X., Free PMC Article

Expression of Programmed Cell Death 1 Ligand 2 in Patients With Thymoma and Thymomatous Myasthenia Gravis.
Zhu H, Zou J, Zeng B, Yang L, Xiao J, Zhang X, Feng Y, Su C.

Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases.
Abdulla M, Sundström C, Lindskog C, Hollander P., Free PMC Article

Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.
Durak Ö, Bozkurt KK, Çiriş İM, Kocer M, Eroğlu HE.

PD-L1 and PD-L2 expression in colorectal cancer.
Zeynep O, Funda C, Evrim Y, Deniz A, Bülent Y, Fatih YN.

Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
Sule Kutlar Dursun F, Alabalik U.

FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.
Davidson C, Taggart D, Sims AH, Lonergan DW, Canel M, Serrels A., Free PMC Article

Exome sequencing identifies PD-L2 as a potential predisposition gene for lymphoma.
Shao J, Gao L, Leung ML, Gallinger B, Inglese C, Meyn MS, Del Gaudio D, Das S, Li Z., Free PMC Article

Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
Takamochi K, Hara K, Hayashi T, Kohsaka S, Takahashi F, Suehara Y, Shimokawa M, Suzuki K.

PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y, Chen X, Mo S, Ma H, Lu Z, Yu S, Chen J., Free PMC Article

DNA Methylation Patterns in the HLA-DPB1 and PDCD1LG2 Gene Regions in Patients with Autoimmune Thyroiditis from Different Water Iodine Areas.
Wan S, Liu L, Ren B, Qu M, Wu H, Jiang W, Wang X, Shen H.

The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X, Lu H, Peng L, Zhou J, Wang M, Li J, Liu Z, Zhang W, Zhao Y, Zeng X, Lu L.

Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.
Sumitomo R, Huang CL, Fujita M, Cho H, Date H., Free PMC Article

Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
Ogawa T, Kan-O K, Shiota A, Fujita A, Ishii Y, Fukuyama S, Matsumoto K., Free PMC Article

PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?
Gül G, Ince D, Olgun N, Ozer E.

Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Ralser DJ, Klümper N, Gevensleben H, Zarbl R, Kaiser C, Landsberg J, Hölzel M, Strieth S, Faridi A, Abramian A, Dietrich D.